Experience with the successful use of topical beta-adrenoblockers in the treatment of infantile hemangiomas: a clinical case and review of the literature
https://doi.org/10.51793/OS.2024.27.5.006
Abstract
Background. Infantile (infantile) hemangiomas are benign vascular tumors found predominantly in the pediatric population. Its presence can lead not only to aesthetic discomfort of the child, but also to gross functional disorders. The etiology of infantile hemangiomas is not fully understood. It is assumed that the development of this neoplasm is based on abnormal proliferation of endothelial cells with disruption of the architectonics of blood vessels due to mutation of genes responsible for the processes of tissue proliferation, or as a consequence of antenotal and/or perinatal hypoxia. Despite the fact that in some cases infantile hemangiomas can resolve spontaneously, the question of their therapy is relevant and is considered in relation to each patient individually. To date, the first line of therapy is the administration of the beta-adrenoblocker propranolol, with marked clinical improvement, but possible development of a number of side effects. Therapy is initiated as early as possible, that is, during the proliferative phase of infantile hemangioma development. The chosen method of treatment should be as effective as possible and should not lead to serious complications and the development of side effects. Since there is no unified approach to the management of such patients in the literature, it is necessary to continue searching for other methods of infantile hemangioma treatment depending on the clinical and morphologic course of the disease.
Conclusion. This article presents a clinical case of infantile hemangioma and the results of topical beta-blocker use as an alternative treatment method to reduce the risk of side effects of the beta-adrenoblocker group of drugs.
About the Authors
R. V. Saranyuk
Limited Liability Company «Center for Medical Examinations and
Prevention»
Russian Federation
Russian Federation
Roman V. Saranyuk, President of the Kursk regional public Organization
«Society of Integrative Dermatology», dermatovenereologist
2 Leninsky Komsomol Avenue, Kursk, 305018, Russia
T. A. Gosteva
Limited Liability Company «Kurchatov Center of Modern Medicine»
Russian Federation
Russian Federation
Tatyana A. Gosteva, Member of the Kursk regional public organization «Society of Integrative Dermatology», therapist, pulmonologist
10 Energetikov Str., Kurchatov, Kursk region, 307250, Russia
References
1. Kukes V. G., Sychev D. A., Andreev D. A. Clinical pharmacology of b-adrenoblockers. Breast cancer. Russkiy meditsinskiy zhurnal. 2005; 14: 932. (In Russ.)
2. Martimyanova L. A., Makienko N. V., Usan N. Yu. Beta-adrenoreceptor blockers in therapeutic clinic. Vestnik KhNU in. V. N. Karazina. Seriya meditsina. 2008;16: 831 (In Russ.).
3. Mashiah J., Kutz A., Rabia S. H., et al. Assessment of the effectiveness of topical propranolol 4% gel for infantile hemangiomas. Int J Dermatol. 2017; 56: 148-153.
4. Al-Haddad C., El Salloukh N. A., El Moussawi Z. β-Blockers in the treatment of periocular infantile hemangioma. Curr Opin Ophthalmol. 2019; 30: 319-325.
5. Oke I., Alkharashi M., Petersen R. A., Ashenberg A., Shah A. S. Treatment of ocular pyogenic granuloma with topical timolol. JAMA Ophthalmol. 2017; 135: 383-385.
6. Chiriac A., Birsan C., Podoleanu C., Moldovan C., Brzezinski P., Stolnicu S. Noninvasive treatment of pyogenic granulomas in young children with topical timolol and trichloroacetic acid. J Pediatr. 2016; 169: 322-322, 322.
7. Neri I., Baraldi C., Balestri R., Piraccini B. M., Patrizi A. Topical 1% propranolol ointment with occlusion in treatment of pyogenic granulomas: an open-label study in 22 children. Pediatr Dermatol. 2018; 35: 117-120.
8. Gupta D., Singh N., Thappa D. M. Is timolol an effective treatment for pyogenic granuloma? Int J Dermatol. 2016; 55: 592-595.
9. Yen C.-F., Hsu C.-K., Lu C.-W. Topical betaxolol for treating relapsing paronychia with pyogenic granuloma-like lesions induced by epidermal growth factor receptor inhibitors. J Am Acad Dermatol. 2018; 78: 143-144.
10. Gupta R., DeBord L., Dao H. Failed treatment of classic Kaposi's sarcoma with topical timolol: case report and review of the literature. Cureus. 2019; 11: e6272.
11. Espadafor-Lopez B., Cuenca-Barrales C., Salvador-Rodriguez L., RuizVillaverde R. Iatrogenic Kaposi's sarcoma successfully treated with topical timolol. Actas Dermosifiliogr. 2020; 111: 176-178.
12. Abdelmaksoud A., Filoni A., Giudice G., Vestita M. Topical timolol for Kaposi sarcoma: an innovation. Australas J Dermatol. 2018; 59: 340-341.
13. Abdelmaksoud A., Filoni A., Giudice G., Vestita M. Classic and HIVrelated Kaposi sarcoma treated with 0.1% topical timolol gel. J Am Acad Dermatol. 2017; 76: 153-155.
14. Thomas B., Kurien J. S., Jose T., Ulahannan S. E., Varghese S. A. Topical timolol promotes healing of chronic leg ulcer. J Vasc Surg Venous Lymphat Disord. 2017; 5: 844-850.
15. Vestita M., Bonamonte D., Filoni A. Topical propranolol for a chronic recalcitrant wound. Dermatol Ther. 2016; 29: 148-149.
16. Rai A. K., Janani K., Rai R. Efficacy of topical timolol versus saline in chronic venous ulcers: a randomized controlled trial. J Cutan Aesthet Surg. 2019; 13: 18-23.
17. Novoa M., Baselga E., Beltran S., et al. Interventions for infantile haemangiomas of the skin. Cochrane Database Syst Rev. 2018; 4: CD006545.
18. Painter S. L., Hildebrand G. D. Review of topical beta blockers as treatment for infantile hemangiomas. Surv Ophthalmol. 2016; 61: 51-58.
19. Weibel L., Barysch M. J., Scheer H. S., et al. Topical timolol for infantile hemangiomas: evidence for efficacy and degree of systemic absorption. Pediatr Dermatol. 2016; 33: 184-190.
20. Ng M. S. Y., Tay Y. K., Ng S. S., Foong A. Y. W., Koh M. J. Comparison of two formulations of topical timolol for the treatment of infantile hemangiomas. Pediatr Dermatol. 2017; 34: 492-493.
21. Zheng L., Li Y. Effect of topical timolol on response rate and adverse events in infantile hemangioma: a meta-analysis. Arch Dermatol Res. 2018; 310: 261-269.
22. Padula C., Nicoli S., Pescina S., Santi P. The influence of formulation and excipients on propranolol skin permeation and retention. Biomed Res Int. 2018; 2018: 1281673.
23. Mannschreck D. B., Huang A. H., Lie E., Psoter K., Puttgen K. Topical timolol as adjunct therapy to shorten oral propranolol therapy for infantile hemangiomas. Pediatr Dermatol. 2019; 36: 283-289.
24. Ying H., Zou Y., Yu W., et al. Prospective, open-label, rater-blinded and selfcontrolled pilot study of the treatment of proliferating superficial infantile hemangiomas with 0.5% topical timolol cream versus 595-nm pulsed dye laser. J Dermatol. 2017; 44: 660-665.
Review
For citations:
Saranyuk R.V., Gosteva T.A. Experience with the successful use of topical beta-adrenoblockers in the treatment of infantile hemangiomas: a clinical case and review of the literature. Lechaschi Vrach. 2024;(5):32-35. (In Russ.) https://doi.org/10.51793/OS.2024.27.5.006
Views:
283
JATS XML
Email this article 
